Skip to content
2000
Volume 1, Issue 4
  • ISSN: 1570-162X
  • E-ISSN: 1873-4251

Abstract

The ability of lentiviral vectors to transduce and stably integrate their genomes into non-dividing cells was the major reason for the development of the HIV-1 based vector gene delivery system. The first VSVG pseudotyped lentiviral vectors fulfilled these expectations by ferrying large genetic payloads to nondividing cells in vitro and in vivo. Here we discuss advances in HIV-1 vector systems which lead to improvement in biosafety, transduction efficiency, longevity and regulation of transgene expression, and vector production. The successful use of the advanced HIV-1 based vector system opened new avenues in establishing transgenic animal models for basic research. Additionally, we describe accomplishments using HIV-1 based vectors to correct pathological courses of incurable diseases in preclinical animal models including Parkinson's disease and β-thalassemia.

Loading

Article metrics loading...

/content/journals/chr/10.2174/1570162033485104
2003-10-01
2025-09-16
Loading full text...

Full text loading...

/content/journals/chr/10.2174/1570162033485104
Loading

  • Article Type:
    Review Article
Keyword(s): animal model; gene therapy; lentiviral vector; pseudotype; tetracycline
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test